In order to receive permission from the Food and Drug Administration (FDA) to treat patients in the United States, WaveLight was required to conduct a strictly controlled clinical study on over 1,200 myopic and hyperopic eyes and then monitor and report the results over a one-year period following the treatments.
The outcomes not only fulfilled the rigid standards of the American regulatory authorities, they exceeded them. Thus WaveLight effectively demonstrated the precision and stability of its laser.